Review

lats2 expression (Addgene inc)

Name: lats2 expression
Brand: Addgene inc
Rating: 86 (1 reviews)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Addgene inc lats2 expression
Lats2 Expression, supplied by Addgene inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lats2 expression/product/Addgene inc
Average 86 stars, based on 1 article reviews

lats2 expression - by Bioz Stars, 2025-03

86/100 stars

Images

Image Search Results

a StarBase bioinformatic tool analyzed potential binding sites between PTBP1 and LATS2 mRNA. b The interaction between PTBP1 and LATS2 mRNA in HCT116 and LoVo cells was verified by RIP assay. c , d The protein (n = 14) and mRNA (n = 28) levels of LATS2 in CRC tissues and adjacent normal tissues were determined by western blotting and RT-qPCR. GAPDH was used as loading control in western blotting. e The relative expression of PTBP1 was detected in HCT116 and LoVo cells transfected with OE-PTBP1, sh-PTBP1#1, or sh-PTBP1#2 plasmid by RT-qPCR. f , g The mRNA and protein expression levels of LATS2 were measured by RT-qPCR and western blotting after overexpressing or knocking down PTBP1. GAPDH was used as loading control in western blotting. h LATS2 mRNA levels in HCT116 and LoVo cells co-transfected with OE-PTBP1+sh- LINC00689 were examined by RT-qPCR after treatment with 2 μg/mL act-D for 0, 4, 8, 12, and 24 h. n = 28 biologically independent samples in clinical results. n = 3 biologically independent experiments in in vitro results. Data were presented as mean ± SD, * P < 0.05, ** P < 0.01, and *** P < 0.001. PTBP1 polypyrimidine tract-binding protein 1, LATS2 large tumor suppressor kinase 2, OE overexpression, NC negative control.

Journal: Communications Biology

Article Title: KLF15 transcriptionally activates LINC00689 to inhibit colorectal cancer development

doi: 10.1038/s42003-023-05757-3

Figure Lengend Snippet: a StarBase bioinformatic tool analyzed potential binding sites between PTBP1 and LATS2 mRNA. b The interaction between PTBP1 and LATS2 mRNA in HCT116 and LoVo cells was verified by RIP assay. c , d The protein (n = 14) and mRNA (n = 28) levels of LATS2 in CRC tissues and adjacent normal tissues were determined by western blotting and RT-qPCR. GAPDH was used as loading control in western blotting. e The relative expression of PTBP1 was detected in HCT116 and LoVo cells transfected with OE-PTBP1, sh-PTBP1#1, or sh-PTBP1#2 plasmid by RT-qPCR. f , g The mRNA and protein expression levels of LATS2 were measured by RT-qPCR and western blotting after overexpressing or knocking down PTBP1. GAPDH was used as loading control in western blotting. h LATS2 mRNA levels in HCT116 and LoVo cells co-transfected with OE-PTBP1+sh- LINC00689 were examined by RT-qPCR after treatment with 2 μg/mL act-D for 0, 4, 8, 12, and 24 h. n = 28 biologically independent samples in clinical results. n = 3 biologically independent experiments in in vitro results. Data were presented as mean ± SD, * P < 0.05, ** P < 0.01, and *** P < 0.001. PTBP1 polypyrimidine tract-binding protein 1, LATS2 large tumor suppressor kinase 2, OE overexpression, NC negative control.

Article Snippet: RT-qPCR detection of KLF15 , LINC00689 , and LATS2 mRNA expression levels was performed with SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s instruction on ABI7900HT (Thermo Fisher Scientific).

Techniques: Binding Assay, Western Blot, Quantitative RT-PCR, Control, Expressing, Transfection, Plasmid Preparation, In Vitro, Over Expression, Negative Control

a LINC00689 , and ( b ) p-YAP1 (S127), YAP1, β-catenin, slug, vimentin, CTGF, CYR61, and HIF1α protein expression in CRC cells co-transfected with OE- LINC00689 and sh-LATS2 were examined by RT-qPCR and western blotting, respectively. β-tubulin was used as loading control for CTGF, and GAPDH was used as loading control for other proteins in western blotting. Red, blue, or purple outlines denote bands that were derived from the same blot. c CRC cell proliferative, ( d ) migratory, and ( e ) invasive abilities were evaluated after overexpressing LINC00689 and silencing LATS2 via CCK-8, wound healing, and transwell assays, respectively. Scale bar: 200 μm in d and 100 μm in e. f Immunofluorescence detection of N-cadherin expression after simultaneous overexpression of LINC00689 and knockdown of LATS2. Green, N-cadherin; Blue, DAPI. Scale bar: 50 μm. n = 3 biologically independent experiments in in vitro results. Data were presented as mean ± SD, * P < 0.05, ** P < 0.01, and *** P < 0.001. LATS2 large tumor suppressor kinase 2, OE overexpression, NC negative control, YAP1 yes-associated protein 1, CTGF connective tissue growth factor, CYR61 cysteine-rich angiogenic inducer 61, HIF1α hypoxia inducible factor 1α.

Journal: Communications Biology

Article Title: KLF15 transcriptionally activates LINC00689 to inhibit colorectal cancer development

doi: 10.1038/s42003-023-05757-3

Figure Lengend Snippet: a LINC00689 , and ( b ) p-YAP1 (S127), YAP1, β-catenin, slug, vimentin, CTGF, CYR61, and HIF1α protein expression in CRC cells co-transfected with OE- LINC00689 and sh-LATS2 were examined by RT-qPCR and western blotting, respectively. β-tubulin was used as loading control for CTGF, and GAPDH was used as loading control for other proteins in western blotting. Red, blue, or purple outlines denote bands that were derived from the same blot. c CRC cell proliferative, ( d ) migratory, and ( e ) invasive abilities were evaluated after overexpressing LINC00689 and silencing LATS2 via CCK-8, wound healing, and transwell assays, respectively. Scale bar: 200 μm in d and 100 μm in e. f Immunofluorescence detection of N-cadherin expression after simultaneous overexpression of LINC00689 and knockdown of LATS2. Green, N-cadherin; Blue, DAPI. Scale bar: 50 μm. n = 3 biologically independent experiments in in vitro results. Data were presented as mean ± SD, * P < 0.05, ** P < 0.01, and *** P < 0.001. LATS2 large tumor suppressor kinase 2, OE overexpression, NC negative control, YAP1 yes-associated protein 1, CTGF connective tissue growth factor, CYR61 cysteine-rich angiogenic inducer 61, HIF1α hypoxia inducible factor 1α.

Techniques: Expressing, Transfection, Quantitative RT-PCR, Western Blot, Control, Derivative Assay, CCK-8 Assay, Immunofluorescence, Over Expression, Knockdown, In Vitro, Negative Control

Transcription factor KLF15 was found to upregulate LINC00689 via binding to its promoter, then the upregulated LINC00689 could enhance the stability of LATS2 mRNA through interacting with PTBP1 protein, thereby inhibiting CRC development by repressing the activation of YAP1/β-catenin pathway.

Journal: Communications Biology

Article Title: KLF15 transcriptionally activates LINC00689 to inhibit colorectal cancer development

doi: 10.1038/s42003-023-05757-3

Figure Lengend Snippet: Transcription factor KLF15 was found to upregulate LINC00689 via binding to its promoter, then the upregulated LINC00689 could enhance the stability of LATS2 mRNA through interacting with PTBP1 protein, thereby inhibiting CRC development by repressing the activation of YAP1/β-catenin pathway.

Techniques: Binding Assay, Activation Assay

Expression of LATS2 in NPC cell lines and NPC tumor tissues . A, The expression levels of LATS2 transcripts in the NPC cell lines CNE1, CNE2, 5-8F and C666-1, and in immortalized primary nasopharyngeal epithelial NP69 cells, as well as in three NPC biopsies and one paired normal epithelium were evaluated by quantitative real-time PCR. The NPC cell lines CNE1, CNE2, 5-8F and C666-1, as well as NPC tumors (NPC1, NPC2 and NPC3) show a higher LATS2 mRNA expression level than immortalized primary nasopharyngeal epithelial NP69 cells and normal nasopharynx epithelium (NPNE1). B, The LATS2 protein expression level was detected by western blot in the NPC cell lines CNE1, CNE2, 5-8F, C666-1 cells and in NP69 cells. C, LATS2 (IHC, × 200) staining revealed that overexpression of LATS2 was observed in the nuclear and cytoplasm of carcinoma cells. D, Weak staining of LATS2 was observed in adjacent normal nasopharyngeal epithelial cells. H&E staining of NPC carcinoma cells (E) and adjacent normal nasopharyngeal epithelial cells (F).

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Expression of LATS2 in NPC cell lines and NPC tumor tissues . A, The expression levels of LATS2 transcripts in the NPC cell lines CNE1, CNE2, 5-8F and C666-1, and in immortalized primary nasopharyngeal epithelial NP69 cells, as well as in three NPC biopsies and one paired normal epithelium were evaluated by quantitative real-time PCR. The NPC cell lines CNE1, CNE2, 5-8F and C666-1, as well as NPC tumors (NPC1, NPC2 and NPC3) show a higher LATS2 mRNA expression level than immortalized primary nasopharyngeal epithelial NP69 cells and normal nasopharynx epithelium (NPNE1). B, The LATS2 protein expression level was detected by western blot in the NPC cell lines CNE1, CNE2, 5-8F, C666-1 cells and in NP69 cells. C, LATS2 (IHC, × 200) staining revealed that overexpression of LATS2 was observed in the nuclear and cytoplasm of carcinoma cells. D, Weak staining of LATS2 was observed in adjacent normal nasopharyngeal epithelial cells. H&E staining of NPC carcinoma cells (E) and adjacent normal nasopharyngeal epithelial cells (F).

Article Snippet: After reverse transcription of the total RNA, the first-strand cDNA was then used as template for detection of LATS2 expression by using quantitative real time PCR (QT-PCR) with the SYBR Green I chemistry (ABI Inc., USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Immunohistochemistry, Staining, Over Expression

Correlation between LATS2 expression and clinicopathological parameters of NPC

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Correlation between LATS2 expression and clinicopathological parameters of NPC

Techniques: Expressing

Kaplan-Meier survival curves of NPC patients . A, The five-year overall survival rate of 220 NPC patients was 66.18%. B, The five-year overall survival rates were 73.96% and 57.23%, in NPC patients whose tumors showed low levels of LATS2 expression (n = 109) and high levels of LATS2 expression (n = 111), respectively; there was a significant difference in the overall survival rate between the two groups ( P = 0.006). C, No significant differences in five-year survival rates were found between low levels of LATS2 expression (n = 29) and high levels of LATS2 expression (n = 25) in NPC patients with early stage disease (stage I - II, P = 0.099). D, The five-year overall survival rates were 70.57% and 57.59% in patients with late stage disease (stage III - IV) whose tumors showed low levels of LATS2 expression (n = 80) and high levels of LATS2 expression (n = 86), respectively; there was a significant difference in the overall survival rate between the two groups ( P = 0.032). E, No differences were found in overall survival between low levels of LATS2 expression (n = 28) and high levels of LATS2 expression (n = 30) in NPC patients with differentiated non-keratinising carcinoma (WHO type II, P = 0.125). F, The five-year overall survival rates were 70.91% and 62.23% in patients with undifferentiated carcinoma (WHO type III) whose tumors showed low levels of LATS2 expression (n = 81) and high levels of LATS2 expression (n = 81), respectively; there was a significant difference in the overall survival rate between the two groups ( P = 0.040).

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Kaplan-Meier survival curves of NPC patients . A, The five-year overall survival rate of 220 NPC patients was 66.18%. B, The five-year overall survival rates were 73.96% and 57.23%, in NPC patients whose tumors showed low levels of LATS2 expression (n = 109) and high levels of LATS2 expression (n = 111), respectively; there was a significant difference in the overall survival rate between the two groups ( P = 0.006). C, No significant differences in five-year survival rates were found between low levels of LATS2 expression (n = 29) and high levels of LATS2 expression (n = 25) in NPC patients with early stage disease (stage I - II, P = 0.099). D, The five-year overall survival rates were 70.57% and 57.59% in patients with late stage disease (stage III - IV) whose tumors showed low levels of LATS2 expression (n = 80) and high levels of LATS2 expression (n = 86), respectively; there was a significant difference in the overall survival rate between the two groups ( P = 0.032). E, No differences were found in overall survival between low levels of LATS2 expression (n = 28) and high levels of LATS2 expression (n = 30) in NPC patients with differentiated non-keratinising carcinoma (WHO type II, P = 0.125). F, The five-year overall survival rates were 70.91% and 62.23% in patients with undifferentiated carcinoma (WHO type III) whose tumors showed low levels of LATS2 expression (n = 81) and high levels of LATS2 expression (n = 81), respectively; there was a significant difference in the overall survival rate between the two groups ( P = 0.040).

Techniques: Expressing

Univariate and multivariate Cox regression analysis of different prognostic varibles in patients with NPC

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Univariate and multivariate Cox regression analysis of different prognostic varibles in patients with NPC

Techniques: Expressing

Methylation-specific PCR analysis of the LATS2 promoter . Mehtylation of the LATS2 promoter was detected in NPC tumor tissues (A) and NPC cell lines (B). MC, a positive control for methylated alleles. UC, a positive control for unmethylated alleles. M, methylated. U, unmethylated. The methylation-specific products (148 bp) and unmethylation-specific products (130 bp) were separated on 2.5% agarose gels. Marker, 50 bp size marker. T, NPC tumor tissue. N, chronic inflammation of nasopharyngeal samples

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Methylation-specific PCR analysis of the LATS2 promoter . Mehtylation of the LATS2 promoter was detected in NPC tumor tissues (A) and NPC cell lines (B). MC, a positive control for methylated alleles. UC, a positive control for unmethylated alleles. M, methylated. U, unmethylated. The methylation-specific products (148 bp) and unmethylation-specific products (130 bp) were separated on 2.5% agarose gels. Marker, 50 bp size marker. T, NPC tumor tissue. N, chronic inflammation of nasopharyngeal samples

Techniques: Methylation, Positive Control, Marker

LATS2 siRNA1 transfection effectively suppresses LATS2 expression . A, The 5-8F cell line was transfected with three siRNAs (50 nM) to target LATS2 or with control siRNA (50 nM). Cell lysates were generated 72 h post-transfection, followed by immunoblot analysis to determine LATS2 expression; GAPDH was used as the loading control. B, Densitometry analysis revealed that 5-8F cells transfected with LATS2 siRNA1 showed a 78% decrease in LATS2 protein expression compared to cells transfected with control siRNA. C, 5-8F cells were transfected with different concentrations (25 nM, 50 nM, 75 nM and 100 nM) of LATS2 siRNA1 or with control siRNA. Cell lysates were generated at 72 h post-transfection, followed by immunoblot analysis to determine LATS2 expression, GAPDH was used as the loading control. D, Densitometry analysis revealed that 5-8F cells transfected with LATS2 siNRA1 (75 nM and 100 nM) showed a 94% decrease in LATS2 protein expression.

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: LATS2 siRNA1 transfection effectively suppresses LATS2 expression . A, The 5-8F cell line was transfected with three siRNAs (50 nM) to target LATS2 or with control siRNA (50 nM). Cell lysates were generated 72 h post-transfection, followed by immunoblot analysis to determine LATS2 expression; GAPDH was used as the loading control. B, Densitometry analysis revealed that 5-8F cells transfected with LATS2 siRNA1 showed a 78% decrease in LATS2 protein expression compared to cells transfected with control siRNA. C, 5-8F cells were transfected with different concentrations (25 nM, 50 nM, 75 nM and 100 nM) of LATS2 siRNA1 or with control siRNA. Cell lysates were generated at 72 h post-transfection, followed by immunoblot analysis to determine LATS2 expression, GAPDH was used as the loading control. D, Densitometry analysis revealed that 5-8F cells transfected with LATS2 siNRA1 (75 nM and 100 nM) showed a 94% decrease in LATS2 protein expression.

Techniques: Transfection, Expressing, Generated, Western Blot

Suppression of LATS2 expression inhibits growth, induces apoptosis and S-phase increase . A, 5-8F and CNE2 cell lines were transfected with LATS2 siRNA1 (75 nM) or control siRNA (75 nM). Cell lysates were generated 72 h post-transfection, followed by immoblot analysis to determine LATS2 expression. GAPDH was used as the loading control. B, Growth curve of 5-8F and CNE2 cells upon LATS2 silencing. Results represent the means ± SD (n = 3).*p < 0.05. C, Flow cytometry analysis of apoptosis by using AnnexinV FITC and PI double staining 72 h after transfection. The percentages of apoptotic 5-8F cells transfected with LATS2 siRNA1 and control siRNA were 42.3% and 18.9%, respectively. In CNE2 cells, the percentages of apoptosis in cells transfected with LATS2 siRNA1 and control siRNA were 34.6% and 17.6%. D. Cell cycle distribution was monitored by flow cytometry. The percentages of cells in S-phase in 5-8F cells transfected with LATS2 siRNA1 and control siRNA were 42.6% and 27.2%, respectively. In CNE2 cells, the percentages of S-phase cells among those transfected with LATS2 siRNA1 and control siRNA were 33.7% and 25.7%, respectively.

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Suppression of LATS2 expression inhibits growth, induces apoptosis and S-phase increase . A, 5-8F and CNE2 cell lines were transfected with LATS2 siRNA1 (75 nM) or control siRNA (75 nM). Cell lysates were generated 72 h post-transfection, followed by immoblot analysis to determine LATS2 expression. GAPDH was used as the loading control. B, Growth curve of 5-8F and CNE2 cells upon LATS2 silencing. Results represent the means ± SD (n = 3).*p < 0.05. C, Flow cytometry analysis of apoptosis by using AnnexinV FITC and PI double staining 72 h after transfection. The percentages of apoptotic 5-8F cells transfected with LATS2 siRNA1 and control siRNA were 42.3% and 18.9%, respectively. In CNE2 cells, the percentages of apoptosis in cells transfected with LATS2 siRNA1 and control siRNA were 34.6% and 17.6%. D. Cell cycle distribution was monitored by flow cytometry. The percentages of cells in S-phase in 5-8F cells transfected with LATS2 siRNA1 and control siRNA were 42.6% and 27.2%, respectively. In CNE2 cells, the percentages of S-phase cells among those transfected with LATS2 siRNA1 and control siRNA were 33.7% and 25.7%, respectively.

Techniques: Expressing, Transfection, Generated, Flow Cytometry, Double Staining

Overexpression of LATS2 stimulated cell growth . A, NP69 cells were transfected with pcDNA3-LATS2 or Vector. Cell lysates were generated at 48 h post-transfection, followed by immunoblot analysis to determine LATS2 expression, GAPDH was used as the loading control. B, Densitometry analysis revealed that NP69 cells transfected with pcDNA3-LATS2 showed a 2.66-fold increase in LATS2 protein expression compared to cells transfected with vector. C, MTT assay was used for analysis of the effect of LATS2 on NP69 cell proliferation. Results represent the means ± SD (n = 3).*p < 0.05.

Journal: BMC Cancer

Article Title: LATS2 is De-methylated and Overexpressed in Nasopharyngeal Carcinoma and Predicts Poor Prognosis

doi: 10.1186/1471-2407-10-538

Figure Lengend Snippet: Overexpression of LATS2 stimulated cell growth . A, NP69 cells were transfected with pcDNA3-LATS2 or Vector. Cell lysates were generated at 48 h post-transfection, followed by immunoblot analysis to determine LATS2 expression, GAPDH was used as the loading control. B, Densitometry analysis revealed that NP69 cells transfected with pcDNA3-LATS2 showed a 2.66-fold increase in LATS2 protein expression compared to cells transfected with vector. C, MTT assay was used for analysis of the effect of LATS2 on NP69 cell proliferation. Results represent the means ± SD (n = 3).*p < 0.05.

Techniques: Over Expression, Transfection, Plasmid Preparation, Generated, Western Blot, Expressing, MTT Assay

(A) Pan-cancer analysis expression of LATS2 based on the TIMER1.0 database. (B) Meta-analysis expression of LATS2 in ESCC in the ONCOMINE database.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: (A) Pan-cancer analysis expression of LATS2 based on the TIMER1.0 database. (B) Meta-analysis expression of LATS2 in ESCC in the ONCOMINE database.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Expressing

Relationship between clinical factors and LATS2 expression in ESCC.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: Relationship between clinical factors and LATS2 expression in ESCC.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Expressing

The differential expression of LATS2 in TCGA (A) , GSE23400 (B) , and GSE161533 (C) datasets.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: The differential expression of LATS2 in TCGA (A) , GSE23400 (B) , and GSE161533 (C) datasets.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Expressing

(A) Top graph represents the scatter plot of LATS2 expression from low to high; the middle graph refers to the scatter plot distribution of survival time and survival status corresponding to LATS2 gene expression in different samples; and the bottom graph represents the expression heat map of LATS2. (B) ROC curve and AUC assessed the performance of LATS2. (C) Kaplan–Meier survival analysis revealed that patients with increased LATS2 expression had longer OS in Asian, grade 2, male, and stage 3.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: (A) Top graph represents the scatter plot of LATS2 expression from low to high; the middle graph refers to the scatter plot distribution of survival time and survival status corresponding to LATS2 gene expression in different samples; and the bottom graph represents the expression heat map of LATS2. (B) ROC curve and AUC assessed the performance of LATS2. (C) Kaplan–Meier survival analysis revealed that patients with increased LATS2 expression had longer OS in Asian, grade 2, male, and stage 3.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Expressing

(A) Gene–gene interaction network for LATS2 and the altered neighboring genes constructed on GeneMANIA. (B) Protein–protein interaction identification on the STRING database.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: (A) Gene–gene interaction network for LATS2 and the altered neighboring genes constructed on GeneMANIA. (B) Protein–protein interaction identification on the STRING database.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Construct

(A) Correlation analysis between LATS2 and other genes in ESCC. (B) GO enrichment analysis about the biological process. (C) GO enrichment analysis about molecular function. (D) GO enrichment analysis about cellular components. (E) KEGG enrichment analysis.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: (A) Correlation analysis between LATS2 and other genes in ESCC. (B) GO enrichment analysis about the biological process. (C) GO enrichment analysis about molecular function. (D) GO enrichment analysis about cellular components. (E) KEGG enrichment analysis.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques:

(A) LATS2 expression correlated with numbers of immune cells. (B) Correlation between LATS2 expression and immune checkpoints. (C) IHC staining of LATS2, CTLA4, and PD‐L1 in ESCC samples.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: (A) LATS2 expression correlated with numbers of immune cells. (B) Correlation between LATS2 expression and immune checkpoints. (C) IHC staining of LATS2, CTLA4, and PD‐L1 in ESCC samples.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Expressing, Immunohistochemistry

(A) Forest plot shows the prognostic value of LATS2 expression according to different immune cell subgroups in ESCC patients. (B) Kaplan–Meier plot was used to estimate the correlation between LATS2 expression and OS in different immune cell subgroups of ESCC patients.

Journal: Frontiers in Genetics

Article Title: Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma

doi: 10.3389/fgene.2022.952528

Figure Lengend Snippet: (A) Forest plot shows the prognostic value of LATS2 expression according to different immune cell subgroups in ESCC patients. (B) Kaplan–Meier plot was used to estimate the correlation between LATS2 expression and OS in different immune cell subgroups of ESCC patients.

Article Snippet: We utilized GraphPad Prism 8.0 to map LATS2 gene expression differences in ESCC.

Techniques: Expressing

LATS2 mRNA expression in CRC tissues and cell lines. (a) LATS2 mRNA expression was significantly decreased in CRC tissues compared with matched adjacent normal tissues. (b-c) In the TCGA database, LATS2 mRNA expression was markedly lower in COAD and READ tissues compared with normal tissues. (d) LATS2 expression was decreased in CRC cell lines compared with a normal intestinal epithelial cell (NCM460). Data were expressed as mean ± SD, * P < 0.05; ** P < 0.01; *** P < 0.001

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: LATS2 mRNA expression in CRC tissues and cell lines. (a) LATS2 mRNA expression was significantly decreased in CRC tissues compared with matched adjacent normal tissues. (b-c) In the TCGA database, LATS2 mRNA expression was markedly lower in COAD and READ tissues compared with normal tissues. (d) LATS2 expression was decreased in CRC cell lines compared with a normal intestinal epithelial cell (NCM460). Data were expressed as mean ± SD, * P < 0.05; ** P < 0.01; *** P < 0.001

Article Snippet: The LATS2 protein expression levels were scored using a Vectra 3.0 Automated Quantitative Pathology Imaging System (PerkinElmer, Waltham, MA, USA), with the staining intensity scored as 0 – (no staining), 1+ (weakly positive), 2+ (moderately positive), or 3+ (strongly positive).

Techniques: Expressing

Representative patterns of LATS2 protein expression in colorectal benign and malignant tissues on TMA sections. (a–b) Colorectal cancer with low or no LATS2 expression. (c–d) Colorectal cancer with high LATS2 expression. (e–f) High-grade intraepithelial neoplasia with low LATS2 expression. (g–h) Low-grade intraepithelial neoplasia with low LATS2 expression. (i–j) Normal surgical margin of colorectal cancer with high LATS2 expression

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Representative patterns of LATS2 protein expression in colorectal benign and malignant tissues on TMA sections. (a–b) Colorectal cancer with low or no LATS2 expression. (c–d) Colorectal cancer with high LATS2 expression. (e–f) High-grade intraepithelial neoplasia with low LATS2 expression. (g–h) Low-grade intraepithelial neoplasia with low LATS2 expression. (i–j) Normal surgical margin of colorectal cancer with high LATS2 expression

Techniques: Expressing

LATS2 expression in colorectal benign and malignant tissues

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: LATS2 expression in colorectal benign and malignant tissues

Techniques: Expressing

Associations of LATS2 protein expression with clinicopathological characteristics in colorectal cancer patients

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Associations of LATS2 protein expression with clinicopathological characteristics in colorectal cancer patients

Techniques: Expressing

Univariate and multivariate analyses of prognostic factors for overall survival in colorectal cancer patients

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Univariate and multivariate analyses of prognostic factors for overall survival in colorectal cancer patients

Techniques: Expressing

Survival analysis of CRC patients by the Kaplan–Meier method. (a) Overall survival in patients with high LATS2 expression was significantly higher than that in patients with low LATS2 expression. (b) Overall survival in patients with stage II or stage III–IV CRC was significantly lower than that in patients with stage 0–I CRC

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Survival analysis of CRC patients by the Kaplan–Meier method. (a) Overall survival in patients with high LATS2 expression was significantly higher than that in patients with low LATS2 expression. (b) Overall survival in patients with stage II or stage III–IV CRC was significantly lower than that in patients with stage 0–I CRC

Techniques: Expressing

Notable immune-related signaling pathways in the high LATS2 expression group. (a) LATS2-activated signaling pathways. (b) Chemokine signaling pathways. (c) Cytokine-cytokine receptor interaction signaling pathways. (d) JAK-STAT signaling pathways. (e) Intestinal immune network for IgA production signaling pathways

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Notable immune-related signaling pathways in the high LATS2 expression group. (a) LATS2-activated signaling pathways. (b) Chemokine signaling pathways. (c) Cytokine-cytokine receptor interaction signaling pathways. (d) JAK-STAT signaling pathways. (e) Intestinal immune network for IgA production signaling pathways

Techniques: Expressing

Correlations of LATS2 expression with tumor microenvironment and immune infiltration levels in CRC. (a) Positive correlation between LATS2 expression and immune score in CRC. (b) LATS2 was positively correlated with tumor-infiltrating immune cells in COAD by TIMER. (c) LATS2 was positively correlated with tumor-infiltrating immune cells in READ by TIMER. (d) LATS2 was positively correlated with tumor-infiltrating immune cells in COAD by ssGSEA. (e) LATS2 was positively correlated with tumor-infiltrating immune cells in READ by ssGSEA

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Correlations of LATS2 expression with tumor microenvironment and immune infiltration levels in CRC. (a) Positive correlation between LATS2 expression and immune score in CRC. (b) LATS2 was positively correlated with tumor-infiltrating immune cells in COAD by TIMER. (c) LATS2 was positively correlated with tumor-infiltrating immune cells in READ by TIMER. (d) LATS2 was positively correlated with tumor-infiltrating immune cells in COAD by ssGSEA. (e) LATS2 was positively correlated with tumor-infiltrating immune cells in READ by ssGSEA

Techniques: Expressing

Correlations between LATS2 expression and marker genes for tumor-infiltrating immune cells using the TIMER database

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Correlations between LATS2 expression and marker genes for tumor-infiltrating immune cells using the TIMER database

Techniques: Expressing, Marker

Correlations of LATS2 expression with NRP1, BCL6, PTPRC, and THBD expression in cancer samples and analysis of the PPI network for LATS2. (a–d) LATS2 was positively associated with NRP1, BCL6, PTPRC, and THBD expression in almost all cancers examined, based on data from the TCGA. (e) Protein-protein network view in the GeneMANIA dataset showing the interaction networks of LATS2

Journal: Bioengineered

Article Title: Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

doi: 10.1080/21655979.2021.1996513

Figure Lengend Snippet: Correlations of LATS2 expression with NRP1, BCL6, PTPRC, and THBD expression in cancer samples and analysis of the PPI network for LATS2. (a–d) LATS2 was positively associated with NRP1, BCL6, PTPRC, and THBD expression in almost all cancers examined, based on data from the TCGA. (e) Protein-protein network view in the GeneMANIA dataset showing the interaction networks of LATS2

Techniques: Expressing

Review

Structured Review

Images

Similar Products

Image Search Results